D. Drucker
Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Biology of incretins: GLP-1 and GIP.
- L. Baggio, D. Drucker
- Medicine
- Gastroenterology
- 1 May 2007
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP)… Expand
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
- D. Drucker, M. Nauck
- Medicine
- The Lancet
- 11 November 2006
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake.… Expand
The biology of incretin hormones.
- D. Drucker
- Biology, Medicine
- Cell metabolism
- 1 March 2006
Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin… Expand
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- Kiwon Ban, M. Noyan-Ashraf, J. Hoefer, Steffen-Sebastian Bolz, D. Drucker, M. Husain
- Medicine
- Circulation
- 6 May 2008
Background— The glucagon-like peptide 1 receptor (GLP-1R) is believed to mediate glucoregulatory and cardiovascular effects of the incretin hormone GLP-1(7-36) (GLP-1), which is rapidly degraded by… Expand
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- D. Drucker, J. Buse, K. Taylor, D. Kendall, for the DURATION-1 Study Group
- Medicine
- The Lancet
- 4 October 2008
BACKGROUND
Exenatide is an incretin mimetic that shares glucoregulatory properties with glucagon-like peptide 1 (GLP-1), and improves glycaemic control, with progressive bodyweight reductions, when… Expand
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.
- M. Claussnitzer, S. Dankel, +16 authors Manolis Kellis
- Biology, Medicine
- The New England journal of medicine
- 2 September 2015
BACKGROUND
Genomewide association studies can be used to identify disease-relevant genomic regions, but interpretation of the data is challenging. The FTO region harbors the strongest genetic… Expand
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.
- D. Drucker, J. Philippe, S. Mojsov, W. Chick, J. Habener
- Biology, Medicine
- Proceedings of the National Academy of Sciences…
- 1 May 1987
Insulin secretion is controlled by a complex set of factors. Although blood glucose levels serve as the major stimulus of insulin secretion in mammals, insulin release is also modulated by amino… Expand
Enhancing incretin action for the treatment of type 2 diabetes.
- D. Drucker
- Medicine
- Diabetes care
- 1 October 2003
OBJECTIVE
To examine the mechanisms of action, therapeutic potential, and challenges inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the treatment of type… Expand
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- M. H. Noyan-Ashraf, M. A. Momen, +7 authors D. Drucker
- Medicine
- Diabetes
- 16 January 2009
OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial… Expand
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1–9)… Expand